PBAC conditionally backs IMDELLTRA: Amgen stock costs EUR 384.30

Published on 10/19/2026 at 09:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 10.05 billion versus USD 9.43 billion consensus. Amgen stock costs EUR 384.30 on October 19, 2026.

Regulatory signal and earnings setup

PBAC recommended IMDELLTRA with conditions after its September 2026 meeting.
Second-quarter revenue reached USD 10.05 billion versus USD 9.43 billion consensus.
Amgen stock traded at EUR 384.30 at 9:48 a.m. CEST at Lang & Schwarz on October 19, 2026.

Fotorealistische moderne Biotech-Produktionsanlage mit Glasfassade, Bioreaktoren und Palmen unter blauem Himmel — Amgen Inc. (ISIN US0311621009) zeigt fotorealistisch eine moderne Biotech-Anlage mit Bioreaktoren in Kalifornien, Illustration mit AI erstellt.

Amgen stock (ISIN US0311621009) was trading at EUR 384.30 at Lang & Schwarz on October 19, 2026 at 9:48 a.m. CEST, while its market capitalization stood at USD 233.8 billion as of October 16, 2026. BioPharmaDispatch reported on October 19, 2026, that Australia's Pharmaceutical Benefits Advisory Committee recommended Amgen's IMDELLTRA with conditions after its September 2026 meeting.

Three events since August

Amgen's second-quarter results on August 4, 2026, included adjusted earnings per share of USD 6.29 against USD 5.62 consensus and revenue of USD 10.05 billion versus USD 9.43 billion expectations, according to MarketBeat. On October 8, 2026, Cantor Fitzgerald raised its price target from USD 400.00 to USD 440.00 while keeping a Neutral rating, as Markets Insider reported. The October 19 recommendation is the latest of the three developments.

What does the latest quarter add?

The numbers show a clear earnings cushion before the next report: revenue exceeded consensus by USD 620.0 million, while adjusted earnings per share beat by USD 0.67 in the second quarter of 2026. The comparison matters because the stock is also being judged against a mixed analyst view. MarketBeat reported an overall Hold consensus and an average target of USD 387.93. That target is USD 44.56 below Cantor Fitzgerald's USD 440.00 target.

Next reporting date

Amgen is scheduled to report third-quarter 2026 results on November 3, 2026, according to MetaCap. The date gives investors the next defined checkpoint for commercial performance and the company's 2026 outlook.

Regulatory access shapes the setup

The conditional Australian recommendation adds a market-access data point for IMDELLTRA, while the latest quarterly figures provide the more immediate financial reference. Amgen's investor materials describe the company as a biotechnology group focused on medicines for serious illnesses and list second-quarter 2026 results among its recent investor materials.

Euro quote before earnings

At Lang & Schwarz, Amgen stock was trading at EUR 384.30 on October 19, 2026 at 9:48 a.m. CEST. The next scheduled reporting date is November 3, 2026. The further course of trading is shown by the continuously updated real-time quote of Amgen stock.